Chao Guanqun, Wang Yingying, Ye Fangxu, Zhang Shuo
Department of Family Medicine, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China.
Department of Gastroenterology, The First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, China.
Yonsei Med J. 2018 Oct;59(8):945-950. doi: 10.3349/ymj.2018.59.8.945.
This study aimed to screen for differentially expressed microRNAs (miRNAs) in the colons of rats with visceral hypersensitivity to build the expression profiles of miRNAs therein and to determine the mechanism of Tongxieyaofang use in the treatment of irritable bowel syndrome (IBS).
Forty Sprague-Dawley rats were divided randomly into four groups: control group, model control group (induced by rectum stimulus and evaluated by abdominal withdraw reaction), treatment control group (normal saline), and Tongxieyaofang group (treated with Tongxieyaofang). We screened for differential expression of colonic mucosal miRNAs using liquid chip technology and verified the expression thereof using reverse transcription-PCR.
The visceral hypersensitivity rat model was successfully established. We found the expression of let-7f, let-7i, miR-130b, miR-29a, miR-132, miR-21, and miR-375 to be up-regulated (<0.05), while the expression of miR-24, miR-31a, miR-192, miR-221, and miR-223 was down-regulated (<0.05) in the visceral hypersensitivity rats. After treatment with Tongxieyaofang, the expression of let-7f, let-7i, miR-130b, miR-29a, miR-132, miR-21, and miR-375 was reduced (<0.05), whereas the expression of miR-24, miR-31a, miR-192, miR-221, miR-223 was increased, compared to the treatment control group (<0.05).
MiRNAs play a pivotal role in visceral hypersensitivity and might be targets in the treatment of IBS by Tongxieyaofang.
本研究旨在筛选内脏高敏大鼠结肠中差异表达的微小RNA（miRNA），构建其表达谱，并确定痛泻要方治疗肠易激综合征（IBS）的机制。
40只Sprague-Dawley大鼠随机分为四组：对照组、模型对照组（直肠刺激诱导并通过腹部撤回反应评估）、治疗对照组（生理盐水）和痛泻要方组（用痛泻要方治疗）。我们使用液相芯片技术筛选结肠黏膜miRNA的差异表达，并通过逆转录-聚合酶链反应验证其表达。
成功建立内脏高敏大鼠模型。我们发现，在内脏高敏大鼠中，let-7f、let-7i、miR-130b、miR-29a、miR-132、miR-21和miR-375的表达上调（<0.05），而miR-24、miR-31a、miR-192、miR-221和miR-223的表达下调（<0.05）。与治疗对照组相比，痛泻要方治疗后，let-7f、let-7i、miR-130b、miR-29a、miR-132、miR-21和miR-375的表达降低（<0.05），而miR-24、miR-31a、miR-192、miR-221、miR-223的表达增加（<0.05）。
miRNA在内脏高敏中起关键作用，可能是痛泻要方治疗IBS的靶点。
